← FDA DRUG APPROVALS

FDA ANDA · ANDA211142

HYDROXYPROGESTERONE CAPROATE

Sponsor: EUGIA PHARMA

APPLICATION
ANDA211142
TYPE
ANDA
ORIGINAL APPROVAL
2019-05-09
LATEST ACTION
2022-05-24
ROUTE
INTRAMUSCULAR
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

HYDROXYPROGESTERONE CAPROATEDiscontinued
HYDROXYPROGESTERONE CAPROATE 1250MG/5ML (250MG/ML) · SOLUTION · INTRAMUSCULAR

Approval history

2022-05-24Labeling · Supplement 1 · standardAP
2019-05-09UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →